Kilitch Drugs (india) Limited

Kilitch Drugs (India) Limited, established in 1978 by the late Mr. Pratap Mehta, is a prominent Indian pharmaceutical company specializing in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations. The company offers products in various dosage forms, including solid, liquid, and parenteral forms, catering to both domestic and international markets. Headquartered in Mumbai, Maharashtra, India, Kilitch Drugs is publicly listed on the Bombay Stock Exchange (BSE) under the ticker symbol 524500 and on the National Stock Exchange of India (NSE) under the ticker symbol KILITCH. As of March 13, 2026, the company's market capitalization was approximately ₹5.54 billion, with a revenue of ₹2.07 billion for the fiscal year ending March 31, 2025. The company employs around 187 individuals, reflecting a growth of 11.31% in its workforce over the past year. For more information, visit their official website at kilitch.com.

Kilitch Drugs operates multiple manufacturing facilities to meet the growing demand for its pharmaceutical products. The Mumbai Unit is equipped with advanced facilities designed for the production of high-precision pharmaceutical products, including sterile preparations such as dry powders for injection (DPI), small volume parenterals (SVP) in ampoules and vials, as well as ophthalmic and nasal solutions, ensuring compliance with global Good Manufacturing Practice (GMP) standards. Additionally, the company has a plant in Pen, Maharashtra, which is currently under construction and is expected to be fully operational by the end of the fiscal year 2025-2026. This facility is designed to meet international regulatory standards, including WHO, EU, and USFDA GMP, and will focus on manufacturing nutraceuticals, injectables, ophthalmic products, and oral solid dosage forms.

The leadership team at Kilitch Drugs (India) Limited is headed by Chairman and Managing Director Mukund P. Mehta, who brings extensive experience to the company. Other key executives include Bhavin M. Mehta, Whole-Time Director and Executive Director, and Mira Mehta, Managing Director. The board also comprises independent non-executive directors such as Venkita Subramanian Rajan and Dipen Jayantilal Jain, who provide strategic guidance and oversight.

Kilitch Drugs (India) Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities adhere to international standards, with approvals from regulatory bodies such as the World Health Organization (WHO) for Good Manufacturing Practice (GMP) and the U.S. Food and Drug Administration (FDA). These certifications facilitate market access and ensure compliance with stringent quality standards. The company's product portfolio includes a range of parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops, catering to various therapeutic areas.

Kilitch Drugs (India) Limited has expanded its footprint into emerging markets, including Africa, Latin America, and Southeast Asia. The company's manufacturing facilities in Ethiopia, for instance, produce a wide range of cephalosporin products, including tablets, capsules, injectables, dry powders for suspension, and syrups. This facility aims to lead in the African markets, fulfilling local demand for high-quality generics previously imported from other countries. Additionally, the company's products are available in various countries across Africa, Latin America, and Southeast Asia, indicating a broad international presence.

Kilitch Drugs (India) Limited has strategically diversified its operations across multiple geographic regions, including India, Africa, and Southeast Asia. This diversification mitigates concentration risk and positions the company to leverage growth opportunities in various markets. The establishment of manufacturing facilities in Ethiopia and the ongoing development of the Pen, Maharashtra plant underscore the company's commitment to expanding its global footprint and enhancing its manufacturing capabilities.

Kilitch Drugs (India) Limited's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulatory standards. The company's product portfolio includes a range of parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops, catering to various therapeutic areas. These products are designed to meet the quality and safety standards required for the U.S. market.

Kilitch Drugs (India) Limited's manufacturing facilities are certified by the World Health Organization (WHO) for Good Manufacturing Practice (GMP), ensuring adherence to international quality standards. The company's products are also manufactured in compliance with European Union (EU) GMP standards, facilitating market access in EU member countries. These certifications reflect the company's commitment to maintaining high-quality manufacturing processes.

Kilitch Drugs (India) Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's manufacturing facilities are approved by the local drug controllers, ensuring compliance with Indian regulatory standards. Additionally, the company's products are registered with the Directorate General of Foreign Trade (DGFT), facilitating export activities.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Kilitch Drugs (India) Limited by regulatory authorities. This suggests that the company maintains a strong compliance record with regulatory standards.

Kilitch Drugs (India) Limited operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. The company's focus on manufacturing a diverse range of pharmaceutical formulations, including parenteral, nasal, and topical products, positions it to compete effectively in various therapeutic areas. While specific market share data is not available, the company's strategic initiatives, such as expanding manufacturing capabilities and obtaining international certifications, enhance its competitive position.

Kilitch Drugs (India) Limited differentiates itself through its extensive experience in the pharmaceutical industry, with over 47 years of expertise. The company's commitment to quality is demonstrated by its WHO-GMP certified manufacturing facilities and adherence to international standards. Additionally, Kilitch Drugs offers a broad product portfolio, including cephalosporins, antimalarials, and ophthalmic and nasal products, catering to a wide range of therapeutic areas.

Kilitch Drugs (India) Limited's current strategic direction focuses on expanding its global presence through the development of manufacturing facilities in key markets, such as the ongoing construction of the Pen, Maharashtra plant. The company's product portfolio spans various therapeutic areas, including antibiotics, antimalarials, and ophthalmic and nasal products, indicating a diversified approach. Looking ahead, Kilitch Drugs aims to strengthen its position in both regulated and emerging markets by leveraging its manufacturing capabilities and commitment to quality.

Kilitch Drugs (India) Limited has a track record of consistent export activity, with a total export value of $1.6 million USD and 49 shipments across two products in one therapeutic category. The company's top products include Piperacillin and Ceftazidime, with market shares of 1.2% and 1.4%, respectively. This indicates a focused product portfolio with a concentration on advanced antibiotics. The company's adherence to international quality standards, as evidenced by its WHO-GMP certifications, underscores its reliability as a supplier.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the company's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA).

• WHO-GMP Certification: Ensure the manufacturing facilities are certified by the World Health Organization for Good Manufacturing Practice.

• EU GMP Certification: Verify compliance with European Union Good Manufacturing Practice standards.

• ISO Certifications: Check for ISO 9001 and ISO 13485 certifications, indicating quality management systems and medical device manufacturing standards.

These certifications can typically be verified through the company's